Ritalin

  • USD 1 - 100 / Piece  [Get Latest Price]
  • 100 Piece/Pieces
  • Narcotic & Adjuvant Drugs
  • Injections,Powder,Suspension,powder
  • Ukraine
  • Tag: Ritalin
  • Supplier - VOLVA ENTERPRISE
  • UkraineUkraine
  • US$1 Million - US$2.5 Million
  • 11 - 50 People
  • Manufacturer,Distributor/Wholesaler
  • North America,South America,Eastern Europe,Southeast Asia,Mid East,Eastern Asia,Western Europe
  • skype
  • Mr.VOLVA
  • +380935-189614
Post Date : February 02
Product Details
Company Profile
Inquiry Records(13)

Item specifics

Narcotic & Adjuvant Drugs
Injections,Powder,Suspension,powder
Ukraine

Specifications

Ritalin hydrochloride, methylphenidate hydrochloride USP, is a mild central nervous system (CNS) stimulant, available as tablets of 5,10, and 20 mg for oral administration; Ritalin (methylphenidate hcl) -SR is available as sustained-release tablets of 20 mg for oral administration. Methylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is

Ritalin®
  hydrochlondemethylphenidate hydrochloride tablets Structural Formula Illustration

Methylphenidate hydrochloride USP is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77.

Inactive Ingredients

Ritalin (methylphenidate hcl) tablets: D&C Yellow No. 10 (5-mg and 20-mg tablets), FD&C Green No. 3 (10-mg tablets), lactose, magnesium stearate, polyethylene glycol, starch (5-mg and 10-mg tablets), sucrose, talc, and tragacanth (20-mg tablets).

Ritalin (methylphenidate hcl) -SR tablets: Cellulose compounds, cetostearyl alcohol, lactose, magnesium stearate, mineral oil, povidone, titanium dioxide, and zein.

Company Related ProductsView the Seller's Products
HBsAg DRUG

HBsAg DRUG

HBsAg DRUG

Hepatitis B surface antigen (HBsAg)-positive kidney transplant recipients have increased liver-related mortality. The impact of lamivudine treatment on patient survival, the optimal time to start treatment, and the feasibility of discontinuing treatment have not been determined. This study examined these issues with a novel management protocol. Serum hepatitis B virus (HBV) DNA levels were measured serially in HBsAg-positive kidney transplant recipients, and lamivudine was administered preemptively to patients with increasing HBV DNA levels with or without elevation of aminotransferase levels. Outcomes of patients who underwent transplantation before or after institution of this preemptive management strategy (in January 1996) were compared. Eleven de novo patients (91.7%) who underwent transplantation between 1996 and 2000 and 15 existing patients (39.5%) who underwent transplantation between 1983 and 1995 received preemptive lamivudine therapy for 32.6 ± 13.3 months. The treatment criteria were met by de novo patients at 8.4 ± 6.2 months (range, 1-18 months) after transplantation. Suppression of HBV DNA and normalization of aminotransferase levels were achieved in all treated patients, and 21.4% had hepatitis B e antigen (HBeAg) seroconversion. The survival of preemptively managed de novo transplant patients was similar to that of HBsAg-negative controls, whereas HBsAg-positive patients who underwent transplantation before January 1996 had inferior survival (relative risk of death, 9.7 [P < .001]; relative risk of liver-related mortality, 68.0 [P < .0001]. Eleven patients (40.7%) developed lamivudine resistance. Discontinuation of lamivudine was attempted in 12 low-risk patients after stabilization and was successful in 5 (41.7%). In conclusion, preemptive lamivudine therapy based on serial HBV DNA levels and clinical monitoring improved the survival of HBsAg-positive renal allograft recipients. Treatment can be discontinued safety in selected patients after stabilization to minimize the selection of drug-resistant HBV mutants.

Detail more >>
H.PYLORI DRUG

H.PYLORI DRUG

H.PYLORI DRUG

H. pylori infection occurs when a type of bacteria called Helicobacter pylori (H. pylori) infects your stomach, usually during childhood. A common cause of peptic ulcers, H. pylori infection is present in about half the people in the world.

Most people don't realize they have H. pylori infection, because they never get sick from it. If you develop signs and symptoms of a peptic ulcer, your doctor will probably test you for H. pylori infection, because it can be treated with antibiotics.

Helicobacter pylori (H. pylori) is a type of bacteria responsible for widespreadinfection with more than 50% of the world's population infected, even though 80% of those infected have no symptoms. H. pylori infection is associated with low grade inflammation of the stomach and duodenum (the first part of the small intestine that empties the stomach).

The bacteria has evolved to survive in the acidic environment of the stomach whereenzymes digest food. The H. pylori bacteria burrow into the cells of the stomach lining and cause low grade inflammation. H. pylori is the most common cause of gastric ulcers and gastritis (gastro=stomach +itis=inflammation). Ten percent of those infected may develop an ulcer. Also, those infected have an increased risk ofstomach cancer and lymphoma.

Interestingly, the presence of the bacteria may decrease the prevalence of esophagitis by decreasing the amount of stomach acid that refluxes back into theesophagus. This in turn leads to a decreased risk for esophageal cancer in those infected with H. pylori. Further, H. pylori seems to decrease the risk of developingasthma and allergies.

H. pylori bacteria is found most frequently in underdeveloped countries; but with improved economic conditions, the rate of infection in the population decreases. The infection rate in the United States is between 20%-30%, however, it is higher in Hispanics, African Americans, and the elderly.

Detail more >>
Talk with SupplierX
MOEN VOLVA:
Can I help you?
Contact Supplier

Selected(1/4)Contact or Compare